Seizure Burden and Quality of Life in Grade 2 IDH-Mutant Glioma

Patients with grade 2 IDH-mutant glioma frequently experience seizures as one of the earliest and most persistent manifestations of their disease. Because these tumors often affect younger adults who may live with their diagnosis for many years, seizure control becomes a critical component of long-term management, influencing independence, cognitive function, employment, and overall quality of life alongside tumor-directed treatment decisions.

In this Special Report, Ugur T. Sener, MD, consultant in the Section of Neuro-Oncology and chair of the Division of Neuro-Oncology at Mayo Clinic, discusses emerging insights surrounding seizure burden and disease management in IDH-mutant diffuse glioma. The conversation is framed around evolving data from the phase 3 INDIGO trial evaluating vorasidenib, with particular attention paid to the relationship between tumor biology, seizure activity, and long-term neurologic outcomes in patients with low-grade glioma.

In this opening episode, Sener provides a clinical overview of seizure burden in grade 2 IDH-mutant glioma, discussing how seizures commonly lead to initial diagnosis and frequently remain an ongoing management challenge throughout the disease course. He also highlights the cumulative impact of epilepsy and anticonvulsant therapy on patient well-being and long-term care.